Brief: Reviva Pharmaceuticals Announces 80% Global Enrollment Update For Pivotal Phase 3 RECOVER Study Evaluating Brilaroxazine For Schizophrenia

Reviva Pharmaceuticals Holdings

22/06/2023 11:52

June 22 (Reuters) - Reviva Pharmaceuticals Holdings,
Inc.  RVPH.O :
    * REVIVA PHARMACEUTICALS ANNOUNCES 80% GLOBAL ENROLLMENT
UPDATE
FOR PIVOTAL PHASE 3 RECOVER STUDY EVALUATING BRILAROXAZINE FOR
SCHIZOPHRENIA
    * REVIVA PHARMACEUTICALS HOLDINGS, INC.: TOPLINE DATA FOR
PHASE 3
RECOVER STUDY EXPECTED IN Q3 2023
    * REVIVA PHARMACEUTICALS HOLDINGS, INC.: ENROLLMENT ONGOING
AT
MULTIPLE SITES IN US, EUROPE, AND ASIA

Source text for Eikon:  ID:nGNX3kZblY 
Further company coverage:  RVPH.O 

 ((reuters.briefs@thomsonreuters.com;))